Back to News
Market Impact: 0.32
Lundbeck's Phase IV Trial Of Eptinezumab Meets Primary Goal In Migraine After Prior CGRP Therapy
Source: Nasdaq
Healthcare & BiotechProduct Launches
H. Lundbeck reported positive Phase IV THRIVE trial results for eptinezumab in adults with migraine who had an inadequate response to one prior CGRP-targeting preventive therapy. The outcome supports eptinezumab’s potential use in a treatment-resistant migraine population and could strengthen its commercial positioning in the CGRP market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
HLUN.B0.72
More News
- One of our most recent defensive buys cleared a hurdle and its stock jumped
- Cullinan initiates FDA filing for lung cancer drug zipalertinib
- Moderna to replace Warner Bros Discovery on Nasdaq 100
- Why McKesson Stock Soared More Than 5% Higher Today
- This biotech making precision medicines for cancer could nearly triple, says JPMorgan
- The Dow's rough month, Micron's revenue surge, Google launches Gemini 4 and more in Morning Squawk